Neurology

Sizes of the outbreaks in the U.S. in 2020 likely reduced by nonpharmaceutical interventions related to COVID-19, such as social distancing

Odds of achieving minimal clinical important difference increased 3.04-fold for care concordant with evidence-based medicine

Authors say known IV drug users who have infective endocarditis should be screened carefully for symptoms of cardiovascular disease

Compared with Jan. to Feb. 2020, prescriptions for antipsychotics, antidepressants, trazodone up from March to Sept. 2020

Continuous quality improvement should minimize delays in door-to-puncture and door-to-reperfusion time

Slightly less cognitive and functional decline seen with donanemab versus placebo at 76 weeks in phase 2 trial

Of nine patients with CORE, six had movement disorders, seven had frontal syndrome, four had brainstem impairment

Effect size varies across countries; smoking and cardiovascular disease substantially attenuate effect size

Declines in global cognition and executive function significantly faster for women, despite higher baseline performance

Event rates for time to first fatal or nonfatal stroke significantly reduced for IPE versus placebo